Somapacitan

Somapacitan Uses, Dosage, Side Effects, Food Interaction and all others data.

Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency. This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily.

Somapacitan was granted FDA approval on 28 August 2020.

Somapacitan stimulates the growth hormone receptor. Somapacitan has a long duration of action as it is given once weekly. It has a moderately wide therapeutic window as an acute overdose may cause hypoglycemia followed by hyperglycemia. Patients should be counselled regarding the risk of increased mortality in patients with critical illness, risk of neoplasms, glucose intolerance in diabetes mellitus, intracranial hypertension, hypersensitivity, fluid retention, hypoadrenalism, hypothyroidism, pancreatitis, lipohypertrophy, and lipoatrophy.

Somapacitan
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Somapacitan
Generic	Somapacitan
Somapacitan Other Names	Somapacitan, Somapacitan (genetical recombination), somapacitan-beco
Type
Formula	C₁₀₃₈H₁₆₀₉N₂₇₃O₃₁₉S₉
Protein binding	Somapacitan is >99% bound to albumin.
Groups	Approved, Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

Somapacitan is a human growth hormone analog subcutaneous injection indicated for adults with growth hormone deficiency.

Somapacitan is indicated as a replacement for growth hormone in adult patients with growth hormone deficiency.

Somapacitan is also used to associated treatment for these conditions: Growth Hormone (GH) Deficiency, Growth Hormone Therapy

How Somapacitan works

Somapacitan binds to the growth hormone receptor and induces intracellular signalling to up-regulate insulin-like growth factor I (IGF-1). IGF-1 causes growth in bones and muscle tissue. Growth hormones more directly cause the fusion of myoblasts and myotubes to cause muscle fibre growth, activate neural stem cells, and induce chondrocyte proliferation.

Toxicity

Patients experiencing an acute overdose of somapacitan may present with fluid retention. Chronic overdose may resemble gigantism or acromegaly. Treat patients with symptomatic and supportive measures to minimize the permanent effects.

Food Interaction

No interactions found.

Volume of Distribution

The approximate volume of distribution of somapacitan is 14.6 L.

Elimination Route

A 0.02mg/kg single dose of somapacitan reaches a C_max of 14.4 ng/mL, with a T_max of 11.1 hours, and an AUC of 475 ng*h/mL. A 0.04mg/kg single dose of somapacitan reaches a C_max of 19.8 ng/mL, with a T_max of 25.6 hours, and an AUC of 777 ng*h/mL. A 0.08mg/kg single dose of somapacitan reaches a C_max of 64.2 ng/mL, with a T_max of 16.6 hours, and an AUC of 2753 ng*h/mL. A 0.12mg/kg single dose of somapacitan reaches a C_max of 142.5 ng/mL, with a T_max of 22.5 hours, and an AUC of 6382 ng*h/mL.